Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approps Amendment Targets Chief Counsel Troy

This article was originally published in The Gray Sheet

Executive Summary

FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts

You may also be interested in...



User Fee Revenue Sums Would Be Unknown By FDA Under House Proposal

A FDL-1bill pending in the House Energy & Commerce Committee would allocate all FDA user fee revenue to a general Treasury fund

User Fee Revenue Sums Would Be Unknown By FDA Under House Proposal

A FDL-1bill pending in the House Energy & Commerce Committee would allocate all FDA user fee revenue to a general Treasury fund

Preemption Redemption: FDA Legal Briefs Stand In For Product Liability Law

FDA's new-found willingness to invoke the federal preemption doctrine in state tort suits may provide device firms with some solace in the absence of product liability reform legislation, but prospects remain unclear for non-original-PMA devices

Related Content

UsernamePublicRestriction

Register

MT020579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel